News
INCPF
2.050
NaN%
--
UBS Reaffirms Their Buy Rating on InnoCare Pharma Ltd. (9969)
TipRanks · 07/17 09:55
InnoCare’s TYK2 Inhibitor Soficitinib Delivers Positive Phase II Results in Non-Segmental Vitiligo
TipRanks · 07/16 09:16
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis
TipRanks · 07/15 11:07
InnoCare Pharma Grants Performance-Linked RSUs Under 2023 Share Award Scheme
TipRanks · 06/30 11:40
InnoCare Shareholders Approve All Resolutions at 2026 AGM
TipRanks · 06/16 13:03
InnoCare Pharma Launches 2026 RMB Share Incentive Scheme with First Grant of Restricted Shares
TipRanks · 06/16 13:01
InnoCare Pharma Names New Joint Company Secretary and Secures Listing Rules Waiver
TipRanks · 06/05 10:57
InnoCare Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
TipRanks · 05/28 21:07
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
TipRanks · 05/28 08:40
InnoCare Wins Australian Approval for Lymphoma Drug Orelabrutinib
TipRanks · 05/27 09:13
Shenwan Hongyuan Remains a Buy on InnoCare Pharma Ltd. (9969)
TipRanks · 05/14 05:26
InnoCare Starts First-in-Human Trial of Oral IL-17 Inhibitor ICP-054
TipRanks · 05/13 11:20
InnoCare Pharma Ltd. (9969) Receives a Buy from UBS
TipRanks · 04/25 00:25
InnoCare Pharma Sets 2026 AGM to Approve 2025 Results and Renew Share Issuance Mandate
TipRanks · 04/24 14:39
InnoCare Pharma Grants RSUs Tied to Revenue and R&D Milestones
TipRanks · 04/24 13:38
InnoCare Pharma Seeks Approval for 2026 RMB Share Incentive Scheme and Wins HKEX Waiver
TipRanks · 04/24 13:38
InnoCare: Strong Orelabrutinib Uptake and Autoimmune Pipeline Drive Target Price Upgrade and Buy Rating
TipRanks · 04/24 10:26
InnoCare Pharma Issues Unaudited PRC-GAAP Q1 2026 Report for STAR Market Compliance
TipRanks · 04/23 11:11
InnoCare Pharma Sets April Board Meeting to Approve Q1 2026 Results
TipRanks · 04/10 09:07
InnoCare Pharma Ltd. (9969) Gets a Buy from UBS
TipRanks · 03/27 00:27
More
Webull provides a variety of real-time INCPF stock news. You can receive the latest news about Innocare Pharma through multiple platforms. This information may help you make smarter investment decisions.
About INCPF
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.